Ropes & Gray represented the underwriters in Rhythm Pharmaceuticals’ (Nasdaq: RYTM) $201 million equity offering, including the full exercise of the underwriters’ $26 million option to purchase additional shares. The transaction closed on July 11.
Rhythm is a global commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases.
The team was led by capital markets partners Tom Danielski and Tristan VanDeventer.
LEGAL DESIRE NEWSLETTER
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
